Among the highest-valued personal business in biotech lastly went public.

Now that it has began trading on the general public market, there are a variety of financiers and people that stand to benefit.

Moderna Therapies, a business establishing treatments based upon messenger RNA, had actually acquired a personal assessment of $7.5 billion. The business is still in the early days of human trials for its treatments, that include cancer treatments in addition to a vaccine for cytomegalovirus, or CMV.

On Thursday, the business stated it had actually raised more than $600 million in the greatest IPO in biotech history, seling shares at $23 each. Since Friday afternoon, the stock was trading down at $22

Find Out More: The president of the business headed for the greatest IPO in biotech history has a remarkably big pay bundle

In its filing to go public, Moderna offered info about just how much Moderna stock the business’s magnates and financiers own.

Here are the greatest winners from the going public:

  • Noubar Afeyan, 56, is Moderna’s chairman. He manages 19.5%, or 58.9 million, of Moderna’s shares. Afeyan is the creator and CEO of Flagship Pioneering, the equity capital company that established Moderna. Afeyan owns 42,201 shares straight, and the rest are owned by Flagship-related funds.
  • St├ęphane Bancel, 46, is Moderna’s CEO. He manages 10%, or 30.9 million, of the business’s shares ahead of Moderna’s strategy to go public. Like Afeyan, Bancel does not hold that whole stake straight. Bancel’s direct ownership is 6.7 million shares.
  • AstraZeneca is a huge pharmaceutical business that purchased Moderna in 2016 Prior to the IPO, AstraZeneca manages 8.4% of Moderna’s shares, or approximately 25.5 million.
  • Timothy Springer, a teacher at Harvard Medical School and a founding financier in Moderna, manages 5.7%, or 17.3 million, of Moderna’s shares.
  • Viking Global Financiers, a hedge fund that at first purchased Moderna in 2015, manages 5.5%, or 16.6 million, of Moderna’s shares.
  • Bob Langer, 70, a teacher at the Massachusetts Institute of Innovation, manages 3.9%, or 11.7 million, of the business’s shares. He belongs to the business’s board and among its scholastic cofounders.
  • Stephen Hoge, 42, is Moderna’s president. Hoge signed up with Moderna in 2013 and ended up being president in2015 He manages 1.3%, or approximately 4 million, of the business’s shares.